The European Commission (EC) has granted approval to Sanofi's Sarclisa in combination with a regimen of bortezomib, ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma  Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...

Following the positive opinion by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on ...

Sanofi’s Sarclisa receives European approval to treat transplant-eligible newly diagnosed multiple myeloma: Paris Saturday, July 26, 2025, 09:00 Hrs [IST] Following the positive ...

The FDA approved Sarclisa for the same indication in September 2024. Sanofi (NASDAQ: SNY) has also filed to have the drug approved for NDMM patients not eligible for ASCT in Japan and in China.

The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed multiple myeloma patients ineligible for stem cell transplants. Sarclisa is ...

Monday, Sanofi SA SNY shared data from the IMROZ phase 3 study of Sarclisa, which enrolled 446 patients with newly diagnosed, transplant-ineligible multiple myeloma. The company says that IMROZ is ...

Positive CHMP opinion based on data from ICARIA-MM, the first randomized Phase 3 trial to evaluate an anti-CD38 in combination with pom-dex Sarclisa in combination with pomalidomide and ...

Paris: Sanofi has announced that the European Commission has approved Sarclisa in combination with bortezomib, lenalidomide, ...

Sanofi’s Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma Approval based on GMMG-HD7 phase 3 study demonstrating that Sarclisa with VRd induction ...